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Methodology of Estimating
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Using National Health Insurance
(NHI) Data
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Abstract
The cost-of-illness (COI) studies convert the burdens associated with certain
illnesses into economic and monetary values so as to measure the socioeconomic
costs that are inevitably incurred by a given society in association with certain
illnesses. The estimated costs provided by COI studies provide an important basis
for estimating the amounts of public health resources spent and productivity losses
incurred and thereby make it possible to quantify the socioeconomic burdens that
illnesses impose on society in general. In this chapter, we review the diverse meth-
odologies and techniques for estimating the socioeconomic burden of disease,
which is widely used in the established literature all over the world, and compare
the pros and cons of each. This chapter introduces the existing COI studies in terms
of their research designs, data selection and value assessment processes, applied
perspectives, and chosen components of costs. Furthermore, this chapter introduces
a real-world example of estimating the national economic burden of disease by
using the National Health Insurance (NHI) data. We hope that this chapter will
help readers better understand and use the COI study.
Keywords: socioeconomic burden of disease, economic burden of disease,
cost of illness, cost of disease, financial burden of disease, disease cost
1. Introduction
The cost-of-illness (COI) studies convert the burdens associated with certain
illnesses into economic and monetary values so as to measure the socioeconomic
costs that are inevitably incurred by a given society in association with certain
illnesses. The estimated costs provided by COI studies provide an important basis
for estimating the amounts of public health resources spent and productivity losses
incurred and thereby make it possible to quantify the socioeconomic burdens that
illnesses impose on society in general. In other words, COI studies provide impor-
tant information for determining the socioeconomic costs of illnesses, which, in
turn, makes it possible to better prioritize public health policy tasks and issues. In
particular, the findings of such studies tend to be straightforward and intuitive and
aid policymakers in making related decisions.
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In this chapter, we review the diverse methodologies and techniques for esti-
mating the socioeconomic burden of disease, which is widely used in the established
literature all over the world, and compare the pros and cons of each. Furthermore,
this chapter introduces a real-world example of estimating the national economic
burden of disease by using the National Health Insurance (NHI) data.
2. Review of methods for estimating the costs of illness
This section introduces the existing COI studies in terms of their research
designs, data selection and value assessment processes, applied perspectives, and
chosen components of costs.
2.1 Study designs
COI studies can be roughly divided into two groups, depending on the
approaches they adopted to estimate the socioeconomic costs of illnesses. These
two approaches are the incidence-based approach and prevalence-based
approach [1–3].
2.1.1 Incidence-based approach
The incidence-based approach involves estimating the socioeconomic cost of a
given illness throughout the entire lifespan of the illness, from its initial stage to the
patientʼs complete recovery or death. This involves estimating not only the eco-
nomic burden currently imposed by the illness but also the cost of future health-
related losses, including those caused by sequela. This approach allows the
researcher to identify economic losses over time, from the present into the future,
but makes it impossible to take into account patients who have already suffered
from the same disease. In other words, the incidence-based approach may not be
well suited to estimating the economic burdens of certain types of illnesses (i.e.,
those that currently have low incidence rates but high prevalence rates) at certain
moments in time.
2.1.2 Prevalence-based approach
Contrary to the incidence-based approach, the prevalence-based approach con-
siders economic burdens accruing from not only existing patients suffering from a
given illness for a fixed period of time but also from future and potential patients.
This approach is well suited to estimating the economic costs of an illness at certain
points in time but may not allow the researcher to estimate the cost accrued
throughout the lifespan of the illness, from its initial stage to the patientʼs complete
recovery (or death). Furthermore, this approach may not be so amenable to esti-
mating the costs of frequent yet short-lived illnesses that do not last long enough for
the researcher to find and identify suitable patients within a given period of time.
The prevalence-based approach is by far the more popular method used in
previous studies. This is because it is important to take into account both new and
existing patients suffering from the given illnesses in order to estimate the socio-
economic costs of those illnesses during certain periods.
The characteristics and pros and cons of these two approaches are summarized
below (Table 1).
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2.2 Data selection
COI studies can also be divided into top-down and bottom-up studies,
depending on how the data used were obtained [4, 5].
2.2.1 Top-down studies
Top-down COI studies make use of data concerning the entire given population,
including the entire range of diseases affecting that population on the national level,
and then separate the diseases one by one to estimate their individual costs. In
Korea, the most favored source of data for such studies is the billing information
kept by the NHIS. Billing data provide a convenient glimpse into the total socioeco-
nomic costs of illnesses in the given society. However, the vast scope of these data
can easily lead researchers to include in their estimates expenses and costs that are
not directly related to the given illness (e.g., costs of prescriptions or medical tests
due to sub-diseases).
2.2.2 Bottom-up studies
Bottom-up COI studies review all relevant individual illnesses and then estimate
the total socioeconomic cost of these illnesses for the given nation. These studies use
the medical records of individual patients to estimate the costs for individual
patients and then expand those estimates to arrive at the total cost for the entire
group of patients affected. While this method affords relatively greater accuracy in
estimation than the top-down method, it is, realistically, quite difficult to estimate
the national socioeconomic cost due to the sheer volume and complexity of the data
on individual patients. There may also be regional disparities in the availability and
use of healthcare services, meaning that the resulting data may fail to represent the
entire given society.
Incidence-based approach Prevalence-based approach
Description • Estimates the economic cost of an
illness throughout its lifespan,
ranging from the initial stage to the
patientʼs complete recovery (or
death)
• Estimates the economic cost of an
illness during a certain period of time
by taking into account the costs
generated by both new and existing
patients
Pros • Allows the researcher to consider not
only the current cost but also the
future cost of an illness and the
sequela it causes and thereby
estimate the economic losses
incurred both in the present and the
future
• Better suited to estimating the
current cost of an illness
• Allows the researcher to consider
both new and existing patients at
given point(s) in time
Cons • Makes it difficult for the researcher
to consider existing patients that
have already been afflicted with the
given illness
• Not applicable to illnesses that, at
present, have high prevalence and
low incidence rates
• Makes it difficult for the researcher
to estimate the total economic cost of
an illness throughout its entire
lifespan
• The researcher may not find patients
suffering from the given illness if the
illness lasts for relatively short spans
of time, despite its high incidence
rate
Table 1.
Comparison of approaches to estimating the socioeconomic costs of illnesses.
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2.3 Value assessment
In general, there are two ways to evaluate and estimate the indirect socioeco-
nomic costs of illnesses (namely, losses of labor and productivity). These are the
human capital approach and the willingness-to-pay (WTP) approach [6, 7].
2.3.1 Human capital approach
The human capital approach is the most commonly used method for estimating
the value of human life and the costs of illnesses. Viewing humans as productive
actors, this approach estimates the current value of a human life as the discounted
future expected income.
In estimating the socioeconomic costs of illnesses, this approach posits patients
as productive actors and applies specific discount rates to the income they would
have earned through their labor in order to estimate their losses of working hours
and resulting losses in productivity. This method equates the costs of death and
illnesses to the losses of future total income that patients could have earned had they
remained healthy. This approachʼs focus on the losses of labor productivity caused
by individualsʼ illnesses reveals the opportunity costs of illnesses and death.
This approach is favored because the data it requires for estimating costs are
relatively readily available and the outcomes of the analysis are relatively less
influenced by the researcherʼs bias or subjective interpretation. Moreover, this
approach translates the direct costs (e.g., costs of healthcare service) and indirect
costs (e.g., losses of productivity) incurred by illnesses into losses of future income,
estimated on the basis of the patientsʼ current income level. However, this approach
may be discriminatory, in effect, against certain underproductive groups, such as
students, housewives, and seniors. Some also criticize the approach for its implied
ethic, i.e., that the value of human life can be measured on the basis of a personʼs
ability to earn income. Finally, the approach also runs the risk of underestimating
the intangible costs of illnesses, such as declines in quality of life and psychological
suffering.
The human capital approach is the approach most commonly taken by the
majority of studies. Compared to the WTP approach, the human capital approach is
less time-consuming, more cost-effective, and better suited to ensuring the objec-
tivity of analysis results, as it excludes the researcherʼs bias. Most importantly, it
clearly quantifies losses of productivity due to illnesses based on patientsʼ income
levels.
2.3.2 Willingness-to-pay approach
Also known as the contingent valuation method, the WTP approach estimates
the economic value of something that is not easily converted into a monetary sum
by surveying how much people would be willing to pay for it. COI studies adopting
this approach ask survey participants how much they would be willing to pay to
maintain or improve their health. This approach acknowledges the very common-
sensical assumption that peopleʼs preferences for things that are not easily mone-
tized can be used to estimate the economic values of those things. However, as this
approach requires people to estimate the economic values of things that they are not
used to monetizing, the answers given by survey participants may not be a reliable
measure of the true value of those things. The questions used to survey peopleʼs
willingness to pay can be either open-ended or close-ended. Open-ended questions
ask participants to state the maximum amounts of money they would be willing to
pay, while close-ended questions provide a few options from which participants
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may choose. Close-ended questions can be further divided into questions that apply
bidding games and that use the dichotomous choice method. Questions using bid-
ding games identify the maximum amounts people would be willing to pay by
presenting them with a series of specific amounts of money and asking them
whether they would be willing to pay such amounts. Questions that use the dichot-
omous choice method, on the other hand, present participants with two options of
monetary sums at each time and proceed to the next pair of options depending on
which of the preceding options the participants chose. The dichotomous choice
method imposes relatively less cognitive burden on participants in deciding the
economic values of certain things and allows them to arrive at a decision even in the
absence of in-depth knowledge of the market situation. However, the answers that
participants choose through this method may be merely the amounts of money they
view as acceptable to pay, and not the maximum amounts of money they would be
willing to pay. In applying this method, it is also difficult for the researcher to
decide the proper intervals between the figures to be presented, meaning that it
may take quite a long time for the researcher to identify the final amount of money
that participants would actually be willing to pay.
The table below provides a summary of the differences between the human
capital approach and the WTP approach (Table 2).
2.4 Perspectives of analysis
The conclusions of analyses on the costs of illnesses may be dramatically differ-
ent depending on which perspective the researchers chose to adopt. Since first
attempted and defined, COI studies have been a popular topic of research and
Human capital approach WTP approach
Description • Assesses the value of oneʼs current
life in terms of oneʼs discounted
future expected income
• Regards humans as productive
actors and estimates the costs of
illnesses as losses of working hours
or productivity
• Surveys people on how much they
would be willing to pay for certain
things
• Estimates the costs of illnesses based
on how much individuals would be
willing to pay to maintain or improve
their health
Pros • Ease of accessing required data.
• Ease of quantifying losses of
productivity caused by illnesses
based on patientsʼ income levels
• Results less influenced by personal
bias
• Able to measure the values of even
things not easily monetized
• Uses peopleʼs tacit preferences for
certain things to estimate the
economic values of those things
• Capable of counting even intangible
costs, such as quality of life and
psychological suffering
Cons • Discriminatory against
underproductive groups, such as
students, housewives, seniors, etc.
• Minimizes human life by measuring
it solely on the basis of individualsʼ
ability to earn income
• Incapable of measuring intangible
costs of illnesses, e.g., declines in
quality of life and psychological
suffering
• Decides the values of things solely on
the basis of peopleʼs subjective
preferences
• Participants may have difficulty
monetizing things that they usually
do not monetize, meaning that their
answers may be less than reliable as a
result
Table 2.
Comparison of approaches to estimating the costs of illnesses.
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debate among many researchers worldwide. Analyses in the established literature
today are largely guided by three perspectives: namely, the payer perspective, the
patient perspective, and the societal perspective [8–11].
2.4.1 Payer perspective
The payer perspective focuses on the costs of illnesses that are paid by insurers
and not patients. In South Korea, these costs are the costs covered by the NHI or the
healthcare costs confirmed by the Health Insurance Review and Assessment Service
(HIRA). These covered costs can be either narrowly construed as only the amounts
paid by the insurer or more broadly construed as including the amounts of
copayments made by patients as well. Taking the broad meaning would thus require
the estimation of the healthcare costs confirmed by the HIRA, which encompass
both the costs paid by the insurer and the copayments made by patients.
2.4.2 Patient perspective
The patient perspective requires the researcher to analyze and estimate the costs
paid by patients due to given illnesses. These costs include the direct healthcare and
non-healthcare costs and indirect costs. The direct healthcare costs include the
copayments made by patients, the non-covered costs, and the costs of informal
medical services, while the direct non-healthcare costs include the expenses
patients have to pay in order to receive medical services, such as transportation
expenses. Finally, the indirect costs include the costs incurred by patients in terms
of time and the costs of caregiving.
2.4.3 Societal perspective
The societal perspective leads to the estimation of the costs estimated from both
the payer and patient perspectives and the losses of societal productivity caused by
the given diseases. In other words, the costs estimated based on this perspective
include the costs of lost labor and productivity due to patients taking leaves of
absence or dying prematurely. These costs may also encompass the costs of declines
in quality of life and the psychological suffering of patients.
The table below summarizes the differences among these perspectives
(Table 3).
2.5 Components of costs
Existing studies that embrace the societal perspective generally posit several
specific components of the costs subject to analysis, including direct costs, indirect
costs, and intangible costs [8, 11–13].
2.5.1 Direct costs
Direct costs refer to the amounts of money spent directly on treating or manag-
ing a given illness or more specifically, the amounts of money spent at medical
institutions for the treatment and management of such illness. These costs can be
further broken down into direct healthcare costs and direct non-healthcare costs.
The direct healthcare costs include the costs of outpatient and/or hospitalization
services and purchasing medications (including prescribed medications) to treat the
given illness. Furthermore, it includes the costs incurred by outpatients and
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hospitalized patients alike due to disease, encompassing covered costs paid by
insurer, copayments paid by patients, non-covered costs, and prescription costs.
The direct non-healthcare costs refer to the expenses paid by patients to visit and
use the services of medical institutions, such as the costs of transportation and
caregiving.
2.5.2 Indirect costs
Indirect costs refer to the losses of labor and productivity that are incurred in
addition to the tangible (financial) costs of an illness. Examples include the amounts
of time taken off (paid) work to go to medical institutions and the loss of future
expected income, not only of patients but also of their family members or other
loved ones who are compelled to care for them. The latter example may also be
expressed as the opportunity costs of being ill, including the losses of working hours
and leisure time.
The indirect costs, or losses of productivity, are estimated by defining the num-
ber of hospitalization days as the number of working days lost and the amounts of
time spent for outpatient visits, as losses of working time. The losses of future
income are due to the premature deaths of patients.
2.5.3 Intangible costs
The intangible costs represent the decline in the quality of life and psychological
suffering of patients and loved ones. However, it is notoriously difficult to define
and quantify these costs with precision (Drummond et al., 2005). Due to the
scarcity of related data and the difficulty of quantification, researchers often forgo
estimating these costs (Table 4).
Type Category Components of
cost
Perspective
Payer
perspective
Patient
perspective
Societal
perspective
Direct Healthcare costs Covered cost ✓ ✓
Copayment ✓ ✓
Non-covered
cost
✓ ✓
Non-healthcare
costs
Cost of
transportation
✓ ✓
Cost of
caregiving
✓ ✓
Indirect Losses of
productivity
Outpatients ✓
Hospitalized
patients
✓
Premature
deaths
✓
Intangible Declines in quality of life,
psychological suffering, etc.
✓
Table 3.
Costs estimated based on different perspectives.
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3. Example of COI research using NHI data
In this section, we present example of estimating cost-of-illness research using
NHI data. This example titled “Socioeconomic Cost of Allergies” estimates the
socioeconomic costs associated with allergic diseases using NHI data in South Korea
[14]. In South Korea, all citizens are compulsory subscribers to the NHI scheme,
which is a type of social insurance, and all medical institutions or health profes-
sionals are required to submit claim data to the NHI to charge the bill for the
medical services. In other words, the NHI has medical information on around 50
million South Koreans. We hope this example will be useful for readers to conduct
cost-of-illness studies.
3.1 Study design and cost components
The present example adopts the prevalence-based approach, because it is
important to take into account both new and existing patients suffering from
allergic diseases during certain periods. As well, this example employs the human
capital approach as the value assessment method, because it clearly quantifies losses
Type Category Costs Definition
Direct Healthcare
costs
Medical
institutions
Covered
cost
Portion of cost confirmed by the HIRA and paid
by insurers
Copayment Portion of cost confirmed by the HIRA and paid
by patients
Non-
covered cost
Cost paid by patients and not confirmed by the
HIRA
Pharmacies Covered
prescription
cost
Cost of prescription drugs paid by insurers
Prescription
copayment
Cost of prescription drugs paid by patients
OTC drug
cost
Cost of purchasing over-the-counter drugs
Non-
healthcare
costs
Cost of transportation Cost of traveling to and from medical
institutions
Cost of caregiving Cost of hiring professional caregivers or
opportunity cost incurred by family members in
providing care
Indirect Losses of
productivity
Outpatients Loss of working hours due to visiting medical
institutions as outpatients
Hospitalized patients Loss of working hours due to hospitalization
Premature deaths Losses of productivity due to death of patients
Intangible Declines in quality of life, psychological
suffering, etc.
Cost associated with declining quality of life and
psychological suffering
Table 4.
Cost components and definitions.
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of productivity due to illness based on patientsʼ income levels. Moreover, it is better
suited to ensuring the objectivity of analysis results, as it excludes the researcherʼs
bias. As for perspective, this study adopts the societal perspective and estimates
both the direct costs paid by the insurer and patients and society-wide losses of
productivity.
As the purpose of this study is to estimate the entire scope of the socioeconomic
costs generated by allergic diseases in South Korea, this study estimates both the
direct and indirect costs. The direct costs are divided into healthcare and non-
healthcare costs, as in previous studies that adopted the societal perspective. The
indirect costs involve losses of productivity. More specifically, the direct healthcare
costs include the costs incurred by outpatients and hospitalized patients,
encompassing covered costs paid by insurer, copayments made by patients, non-
covered costs, and prescription costs. The direct non-healthcare costs involve all
expenses associated with visiting medical institutions, whether as outpatients or
hospitalized patients, and receiving services for the treatment and management of
allergic diseases, including the costs of transportation and caregiving. The indirect
costs, or losses of productivity, are estimated by defining the number of hospitali-
zation days as the number of working days lost and the amounts of time spent for
outpatient visits, as losses of working time. The losses of future income due to the
premature deaths are estimated for patients aged 15–69 (patients outside of this age
bracket are excluded, as, in accordance with the law, they constitute the non-
working-age population). Due to the absence of objective data, however, intangible
costs are not estimated in this example. The figure below summarizes the compo-
nents of costs estimated in this study (Table 5).
3.2 Data source and case definition
To analyze the socioeconomic costs due to allergic diseases in South Korea, this
study used the 2014 National Patient Sample (NPS) derived from NHI data that
were collected by the HIRA. In South Korea, almost all citizens (98% or higher) are
compulsory subscribers to the NHI scheme, which is a type of social insurance, and
all medical institutions are required to submit claim data to the HIRA to charge the
bill for the medical services they provided when patients visited the medical insti-
tution. Consequently, the HIRA has medical information on around 50 million
South Koreans. The NPS is the data of patients sampled from the large amount of
claim data held by the HIRA, and it is an abridged version of claim data that contain
1-year information regarding medical treatments and prescriptions of the sampled
patients. The data contain the information of about 1.4 million patients, who repre-
sent a sample of 3% of all patients.
Direct costs Healthcare costs Covered cost
Copayment
Non-covered cost
Cost of medications
Non-healthcare costs Cost of transportation
Cost of caregiving
Indirect costs Losses of productivity
Table 5.
Components of estimated costs in this example.
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The NHI data is administrative data, and the prevalence rate is influenced by the
case definition of disease. In other words, prevalence rates can vary dramatically
depending on how the cases are defined. Most of previous studies that made use of
administrative data including NHI data generally used primary diagnoses to esti-
mate prevalence rates. This approach, however, carries the risk of either
underestimating or overestimating the prevalence rates. This study therefore
applied more rigorous criteria in defining prevalence. First, it identified and
extracted patients whose primary and secondary diagnoses were indicated using the
ICD-10 codes for allergic diseases. Of these patients, this study identified those who
had been hospitalized or made at least two outpatient visits each for allergic diseases
and had been prescribed drugs commonly used to treat allergic diseases (as indi-
cated in their insurance billing records), such as nedocromil sodium, oral steroids,
ventolin, and so on. Only patients meeting these rigorous criteria were admitted
into this study as patients.
3.3 Estimation methods
The sources of data for each component of the costs estimated in this study—
including direct and indirect costs—are as follows.
3.3.1 Direct costs
Direct costs refer to the amounts of spending directly related to illness and are
divided into healthcare and non-healthcare costs.
Direct healthcare costs are the costs of preventing, treating, or managing ill-
nesses by using medical institutions and include the costs of outpatient services,
hospitalization, and medications (prescriptions). The majority of existing studies
that estimate direct healthcare costs rely on administrative and official statistics for
their estimations. As there is little controversy over the use of administrative and
official statistics in estimating the direct healthcare costs of illness, this study, also,
uses the NHI data to estimate the direct healthcare costs of allergic diseases.
Depending on who pays them, direct healthcare costs can be further broken down
into covered costs paid by insurer, copayments made by patients, and non-covered
costs also paid by patients. The formula used to estimate the direct healthcare costs
is provided below.
DHC ¼
X
s
X
y
Eisy 1þ αð Þ þ Eosy 1þ βð Þ
 
(1)
where DHC = Direct healthcare costs, s = Sex, y = Age, E = Costs, i = Hospitalized
patients, o = Outpatients, α = Non-covered cost ratio (hospitalized patients),
β = Non-covered cost ratio (outpatients).
The direct non-healthcare costs are the costs of transportation and caregiving
incurred by patients in seeking and receiving the services of medical institutions.
This study draws upon the national official statistics data on transportation costs.
This data include information on the costs of one-way transportation paid by out-
patients and hospitalized patients and estimate the final costs of transportation
based on the assumption that some patients would be accompanied by their care-
givers. The costs of one-way trips were multiplied by the price-adjusted index and
used to estimate the total costs of round-trip transportation. As for the cost of
caregiving, this study used the average daily cost of hiring a caregiver, as suggested
by the caregivers association. Defining the cost of caregiving as the opportunity cost
of caregiversʼ time during patientsʼ hospitalization, this study applied the average
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daily wage for caregivers as the unit cost of caregiving. This unit cost was then
multiplied by the number of hospitalization days. The cost of caregiving was also
estimated for outpatient visits based on the assumption that each outpatient visit
takes up one-third of the caregiverʼs daily working hours. The formula used to
estimate the direct non-healthcare costs is provided below.
NHC ¼
X
s
X
y
Nisy þNosy
 
 Ct 2
 
þ
X
s
X
y
Lisy  Cc
 
þ
1
3
ð Nosy  Cc
  
(2)
where NHC = Direct non-healthcare costs, s = Sex, y = Age, N = Number of
visits, i = Inpatients, o = Outpatients, Ct = Cost of transportation, L = Length of stay,
Cc = Cost of caregiving.
3.3.2 Indirect costs
Indirect costs do not represent actual financial costs paid but the losses of labor
and productivity due to illnesses. The indirect costs represent the amounts of
working time lost in order to visit and use the services of medical institutions, the
loss of future income due to the premature death of patients, and the opportunity
cost of caregiving. The opportunity costs so incurred include not only the amount of
working time lost but also the amount of leisure time lost. This study draws upon
the employment and labor statistics provided by the government in order to esti-
mate the indirect costs. These statistics are part of the official employment and
labor statistics that provide information on the average daily and monthly wages,
total working hours, and employment rates by sex and age.
The losses of labor (productivity) due to the need for treatment and recovery
and losses of future income due to premature death were estimated in the following
manner. First, loss of labor can be understood as the opportunity cost of labor
incurred by spending time hospitalized or making outpatient visits to medical
institutions instead of working. These opportunity costs were thus estimated for the
working-age population (ages 15–69). In the case of hospitalized patients, loss of
productivity was found by multiplying the daily average wage for each age group by
the number of hospitalization days. For outpatients, the daily average wage for each
age group was multiplied by the number of outpatient visits made, and the result
was divided by 3 (based on the assumption that outpatient visits took up one-third
of each patientʼs daily working hours). The formula used to estimate the losses of
productivity is provided below.
PL ¼
X
s
X
y
Nisy þ
1
3
Nosy
 	
W sy  Esy
 
(3)
where PL = Productivity loss, s = Sex, y = Year, N = Number of hospitalization
days (visits), i = Inpatients, o = Outpatients, W = Average wage, E = Employment
rate.
The loss of future income due to the premature death of patients represents the
decrease in expected income that individuals could have earned had they lived to
their full life expectancy. To estimate this loss, this study relied upon the raw data
for the official statistics on causes of death provided by the government to identify
the number of deaths by sex and age and then applied the death rate to the average
monthly wage and number of working days for each age group. The loss of future
income was again estimated for the working-age population (ages 15–69) only,
applying the employment rate of each age group. In order to convert the estimated
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loss of future income into a present value, a discount rate was applied, and the
sensitivity to changes in the discount rate was checked by applying additional
discount rates. The formula used to estimate the loss of future income due to
premature death is shown below.
LFI ¼
X
s
X
y
Xn
k¼1
Nsy 
Ysy tþ kð Þ  Psy tþ kð Þ
1þ rð Þk
 !
(4)
where LFI = Loss of future income, s = Sex, y = Age, k = 1,2,… , n (where “n”
represents the difference between the life expectancy and actual average age at
death for each age cohort), t = Age at death, r = Discount rate, Nsy = Number of
premature deaths associated with allergic diseases by sex and age, Ysy(t + k) =
Annual average income at t + k by sex and age, Psy(t + k) = Employment rate at
t + k by sex and age.
4. Conclusions
The COI study measures socioeconomic losses from certain diseases in a coun-
try. Therefore, it can provide basic information and evidence that is very important
for policy prioritization and resource allocation. For these reasons, many countries
are using the COI study to establish health policies. In particular, the COI study has
the advantage that it is easy to understand not only policymakers but also the
general public by converting national losses from diseases into monetary value.
In this chapter, we reviewed various methodologies and techniques for estimat-
ing the socioeconomic burden of disease. As well, we presented an example of COI
study. We hope that this chapter will help readers better understand and use the
COI study.
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